The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the ...

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

Fundraising in the private-markets business can be tough. Wining and dining big investors for each new vehicle creates an endless treadmill. Worse, the typical closed-end fund structure ignores ...

Rising health insurance exhange enrollment, paired with stricter Medicare marketing rules, attracted rogue actors to the ...

Bain Capital LP is raising a S$460 million ($340 million) loan to back its purchase of Blackstone Inc.’s Singapore-based ...

Global sales of consumer products grew more slowly in 2024 as unsustainable price increases ran their course and volumes only ...

Index was cofounded in late 2023 by Simon Kubica, who spent five years at Atlassian and Christian Iacullo, who spent similar ...

SelectQuote shares surged ~30% on strong Q2 results and a $350M Bain Capital-led investment. Revenue grew 19%. Click to see why I am cautious on SLQT stock.

The EV maker's investors have to weigh what CEO Elon Musk’s bid to gain control of the ChatGPT creator means for his time and ...

Capital expenditures among retailers are projected to reach $55 billion, marking an average of around 7% year-on-year growth ...